NIDDK Central Repository - Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.

An official website of the United States government

NIDDK Central Repository

Publication Information

DOI

10.1371/journal.pone.0009032

PubMed ID

20140258

Public Release Type

Journal

Publication Year

2010

Affiliation

Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St. Louis, Missouri, United States of America.

Authors

Aurora R, Cannon NA, Di Bisceglie AM, Donlin MJ, Li J, Tavis JE, Virahep-C Study Group, Wahed AS

Studies

Virahep-C

Citation

Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, Tavis JE, Virahep-C Study Group. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. PLoS One 2010 Feb 3;5(2):e9032.

Abstract

Hepatitis C virus (HCV) has six major genotypes, and patients infected with genotype 1 respond less well to interferon-based therapy than other genotypes. African American patients respond to interferon alpha-based therapy at about half the rate of Caucasian Americans. The effect of HCV's genetic variation on treatment outcome in both racial groups is poorly understood.